SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: Sir Auric Goldfinger who wrote (246)10/21/1999 9:58:00 AM
From: DLJMT  Respond to of 566
 
You are the one being used here.

from the p.r.:
Monday October 11, 8:00 am Eastern Time
Company Press Release
Cell Pathways Closes Private Financing
HORSHAM, Pa.--(BW HealthWire)--Oct. 11, 1999--Cell Pathways, Inc. (Nasdaq: CLPA - news) today announced that the company has agreed to sell 1.555 million shares of Cell Pathways common stock at $9.00 per share for a total amount of approximately $14 million dollars. For each share purchased, the buyers also receive one warrant, expiring on December 31, 2000, that enables them to purchase an additional share of Cell Pathways common stock at $14 per share.

Janney Montgomery Scott was the placing agent for the private offering. Participants included four funds managed by Morgan Stanley Dean Witter Investment, including the Van Kampen American Value Fund; one fund managed by Miller, Anderson & Sherrerd, LLP; and two funds managed by AIG Capital Management. Also participating in the offering were previous Cell Pathways investors Vulcan Ventures, Inc., and Jackson Boulevard Capital Management.

''This financing provides additional support for our expanding clinical investigations with both Aptosyn(TM) (exisulind) and CP461,'' said Robert J. Towarnicki, Cell Pathways president and chief executive officer. ''It also provides further resources for our continuing preparations for the initial commercialization of Aptosyn(TM).''




To: Sir Auric Goldfinger who wrote (246)10/21/1999 10:00:00 AM
From: DLJMT  Respond to of 566
 
BTW, that was Vulcan's second major investment in CPI.



To: Sir Auric Goldfinger who wrote (246)10/21/1999 12:40:00 PM
From: tuck  Read Replies (1) | Respond to of 566
 
Auric,

Just how far down do you expect CLPA to go? You've gotten a nice plunge, and who knows what the FDA will do next? In your shoes I would take my gain and find other riper shorts. But you're the pro.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News